Introducing The Nautilus™ Smart ECMO Module

The Nautilus™ is cleared by FDA and has obtained CE (Conformité Européenne) Mark for Extracorporeal Membrane Oxygenation (ECMO), enabling support of patients with respiratory and cardiopulmonary failure.

The device oxygenates blood, removes carbon dioxide, regulates blood temperature and provides real-time hemodynamic performance data. It’s the first device that combines the capabilities of a long-term, plasma-tight Polymethylpentene (PMP) hollow fiber ECMO oxygenator and the integration of real time, at-a-glance device monitoring into one disposable life-support device.

Newly Cleared by FDA(ce) for ECMO

Our Legacy.

The original MC3 was founded in 1991 by Robert Bartlett M.D. and Scott Merz PhD as a spin-off from the University of Michigan. For over 20 years the Company developed intellectual property related to extracorporeal artificial hearts and lungs while contributing important translational research to the extracorporeal life support community. In 2013 Robert Foster, acquired the company and formed the new MC3 Cardiopulmonary, turning the small research group into a commercially focused ECMO and related device manufacturer.

Our Purpose.

MC3 Cardiopulmonary believes in purposeful innovation. Our mission is to serve the global community by creating life restoring medical devices that address acute and chronic unmet cardiopulmonary clinical needs. Advances in Extracorporeal Membrane Oxygenation (ECMO) make it one of the most advanced life support technologies in existence for patients failing traditional therapies such as the ventilation. ‍MC3, together with the ECMO Community, is working to transform healthcare by delivering ECMO to patients suffering from acute respiratory and cardiac failure across a broad therapy spectrum.